Endocrine outcome and seminal parameters in young adult men born with hypospadias: A cross-sectional cohort study.


Journal

EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 07 11 2021
revised: 18 04 2022
accepted: 06 06 2022
pubmed: 28 6 2022
medline: 20 7 2022
entrez: 27 6 2022
Statut: ppublish

Résumé

Hypospadias affects around 1/200 newborn males. Intrauterine testicular dysfunction may underlie a subset of cases. The long-term endocrine and reproductive outcomes in these men remain largely unknown. Cross-sectional study in Ghent and Vienna University Hospitals to assess the endocrine and seminal parameters of young adult men (16-21 years) born with non-syndromic hypospadias (NSH) (n = 193) compared to healthy typical males (n = 50). Assessments included physical exam, semen analysis, hormone assays and exome-based gene panel analysis (474 genes). All participants had experienced a spontaneous puberty, in spite of higher LH and INSL3 levels than typical males. Oligo- or azoospermia was observed in 32/172 (18·6%; 99%-CI: 12·2-27·4%) of NSH men; but in 5/16 (31·3%; 99%-CI: 11·1;62·4%) of complex NSH men and in 13/22 (59·1%; 99%-CI: 33·2-80·7%) of those born small for gestational age (SGA). No (likely) pathogenic coding variants were found in the investigated genes. Suboptimal statural growth affected 8/23 (34·8%; 99%-CI: 15·4-61·0%) of men born SGA with NSH. Spermatogenesis is significantly compromised in NSH men, especially in those born SGA or those with complex NSH. Long-term andrological follow-up is recommended, including end-pubertal semen analysis. No clear monogenic causes could be demonstrated in our cohort even in proximal or complex NSH. Being born SGA with NSH is frequently associated with poor catch-up growth, requiring growth hormone therapy in some. Research grants from the European Society of Paediatric Endocrinology, the Belgian Society of Pediatrics, the Belgian Society of Pediatric Endocrinology and Diabetology and the Research Foundation Flanders (FWO).

Sections du résumé

BACKGROUND BACKGROUND
Hypospadias affects around 1/200 newborn males. Intrauterine testicular dysfunction may underlie a subset of cases. The long-term endocrine and reproductive outcomes in these men remain largely unknown.
METHODS METHODS
Cross-sectional study in Ghent and Vienna University Hospitals to assess the endocrine and seminal parameters of young adult men (16-21 years) born with non-syndromic hypospadias (NSH) (n = 193) compared to healthy typical males (n = 50). Assessments included physical exam, semen analysis, hormone assays and exome-based gene panel analysis (474 genes).
FINDINGS RESULTS
All participants had experienced a spontaneous puberty, in spite of higher LH and INSL3 levels than typical males. Oligo- or azoospermia was observed in 32/172 (18·6%; 99%-CI: 12·2-27·4%) of NSH men; but in 5/16 (31·3%; 99%-CI: 11·1;62·4%) of complex NSH men and in 13/22 (59·1%; 99%-CI: 33·2-80·7%) of those born small for gestational age (SGA). No (likely) pathogenic coding variants were found in the investigated genes. Suboptimal statural growth affected 8/23 (34·8%; 99%-CI: 15·4-61·0%) of men born SGA with NSH.
INTERPRETATION CONCLUSIONS
Spermatogenesis is significantly compromised in NSH men, especially in those born SGA or those with complex NSH. Long-term andrological follow-up is recommended, including end-pubertal semen analysis. No clear monogenic causes could be demonstrated in our cohort even in proximal or complex NSH. Being born SGA with NSH is frequently associated with poor catch-up growth, requiring growth hormone therapy in some.
FUNDING BACKGROUND
Research grants from the European Society of Paediatric Endocrinology, the Belgian Society of Pediatrics, the Belgian Society of Pediatric Endocrinology and Diabetology and the Research Foundation Flanders (FWO).

Identifiants

pubmed: 35759917
pii: S2352-3964(22)00300-0
doi: 10.1016/j.ebiom.2022.104119
pmc: PMC9249999
pii:
doi:

Substances chimiques

Testosterone 3XMK78S47O
Luteinizing Hormone 9002-67-9

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104119

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors report no conflicts of interest.

Auteurs

Lloyd J W Tack (LJW)

Department of Internal Medicine and Pediatrics, Ghent University and Pediatric Endocrinology Service, Department of Pediatrics, Ghent University Hospital, Ghent, Belgium.

Anne-Françoise Spinoit (AF)

Department of Urology, Ghent University Hospital, Ghent University, Ghent, Belgium.

Piet Hoebeke (P)

Department of Urology, Ghent University Hospital, Ghent University, Ghent, Belgium.

Stefan Riedl (S)

Division of Pediatric Pulmonology, Allergology and Endocrinology, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria; St Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.

Alexander Springer (A)

Department of Pediatric Surgery, Medical University of Vienna, Vienna, Austria.

Ursula Tonnhofer (U)

Department of Pediatric Surgery, Medical University of Vienna, Vienna, Austria.

Manuela Hiess (M)

Department of Pediatric Urology Ordensklinikum Linz, Hospital of the Sisters of Charity, Linz, Austria.

Julia Weninger (J)

Department of Pediatric Surgery, Medical University of Vienna, Vienna, Austria.

Ahmed Mahmoud (A)

Department of Endocrinology/Andrology, University Hospital Ghent, Ghent, Belgium.

Kelly Tilleman (K)

Department for Reproductive Medicine, Ghent University Hospital, Ghent, Belgium.

Erik Van Laecke (E)

Department of Urology, Ghent University Hospital, Ghent University, Ghent, Belgium.

Anders Juul (A)

Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Denmark.

Jakob Albrethsen (J)

Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.

Elfride De Baere (E)

Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.

Julie Van De Velde (J)

Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.

Hannah Verdin (H)

Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.

Martine Cools (M)

Department of Internal Medicine and Pediatrics, Ghent University and Pediatric Endocrinology Service, Department of Pediatrics, Ghent University Hospital, Ghent, Belgium. Electronic address: Martine.Cools@ugent.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH